Ge Long Hui·2026-03-28 07:23Core Viewpoint - The company reported its 2025 performance, meeting market expectations with a revenue of 31.83 billion yuan, a year-on-year increase of 10%, and a net profit attributable to shareholders of 2.34 billion yuan, up 22% year-on-year [1] Revenue Growth - The company's overall revenue growth is driven by innovative products, with segment revenues as follows: oncology revenue reached 13.18 billion yuan (YoY +23%), liver/cardiovascular metabolism revenue at 6.69 billion yuan (YoY +19%), surgical/analgesia revenue at 5.03 billion yuan (YoY +13%), and respiratory/immunology revenue at 2.82 billion yuan (YoY -11%) [1] - Innovative product revenue for 2025 amounted to 15.22 billion yuan, representing a 26% year-on-year growth, increasing its revenue share to 47.8% [1] R&D Pipeline - The company continues to enhance its R&D pipeline, with ongoing clinical trials for various oncology treatments, including EGFR/c-Met bispecific antibodies entering Phase III for NSCLC and CCR8 monoclonal antibodies in registration trials for MSI-H/dMMR solid tumors and second-line gastric cancer [2] - In chronic disease management, the company is developing multiple weight-loss pipelines and next-generation siRNA therapies for cardiovascular diseases, with Lp(a) siRNA currently in Phase II clinical trials in China and the U.S. [2] Strategic Acquisitions - In July 2025, the company fully acquired Lixin Pharmaceutical to deepen its oncology portfolio, gaining access to leading antibody discovery and ADC technology platforms [2] - In January 2026, the company fully acquired Hejiya, obtaining the world's first clinically validated long-acting (annual injection) liver-targeted siRNA delivery platform, entering the chronic disease market [2] - The company plans to license global rights for Rovaxitinib, approved by NMPA in February 2026, to Sanofi, with an upfront payment of 135 million USD and potential total payments of up to 1.53 billion USD plus sales royalties, indicating a promising future revenue source from licensing [2] Profit Forecast and Valuation - The company has adjusted its net profit forecasts for 2026 and 2027 upwards by 3% and 2% respectively, estimating adjusted net profits of 5.06 billion yuan and 5.56 billion yuan [3] - The current stock price corresponds to adjusted P/E ratios of 19.5 and 17.5 for 2026 and 2027, maintaining an outperform rating with a target price of 8.90 HKD, suggesting a 51% upside potential from the current stock price [3]